quinupristin Report issue

Small molecule Approved FDA Accelerated Approval FDA Priority Review FDA

Active Ingredient History

  • Now
Quinupristin is an antibiotic compound and a semisynthetic derivative of pristinamycin Ia. Quinupristin is a combination of three peptide macrolactones. Quinupristin is used in combination with dalfopristin, another antibiotic, under the trade name Synercid. Synercid is indicated for treatment of complicated skin and skin structure infections caused by methicillin-susceptible Staphylococcus aureus or Streptococcus pyogenes. The mechanism of action of quinupristin is inhibition of the late phase of protein synthesis in the bacterial ribosome. Quinupristin binds to 23S rRNA within the 50S ribosomal subunit and prevents elongation of the polypeptide as well as causing incomplete chains to be released. Adverse reactions to Synercid include inflammation at infusion site, rash, nausea, vomiting and others.   NCATS

  • SMILES: CC[C@H]1NC(=O)[C@@H](NC(=O)C2=C(O)C=CC=N2)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@@H]3CC(=O)[C@H](CS[C@@H]4CN5CCC4CC5)CN3C(=O)[C@H](CC6=CC=C(C=C6)N(C)C)N(C)C(=O)[C@@H]7CCCN7C1=O)C8=CC=CC=C8
  • Mol. Mass: 1022.218
  • ALogP: Missing data
  • ChEMBL Molecule:
More Chemistry

Combination drugs

( quinupristin, dalfopristin (Synercid) - other name: dalfopristin/quinupristin )
5delta-(3-quinuclidinyl)thiomethylpristinamycin ia | quinupristin | quinupristin mesilate | quinupristin mesylate | rp 57669 | rp-57669


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue